A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT04231747 · COMPLETED

Trial details

NCT number: NCT04231747
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma Non-Hodgkin Agressive Lymphoma Diffuse-large B-cell Lymphoma (DLBCL)

Start date: 2020-05-21
Primary completion: 2024-02-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.